Filed in archive
Drugs, Vaccines and Therapeutics
by ruth on February 27, 2006
Amgen released the results of Phase 2 clinical trials for Denosumab (previously referred to as AMG 162), showing that the RANK Ligand inhibitor significantly increased bone mineral density (BMD) in the total hip, lumbar spine, distal 1/3 radius and total body. Results are published in the recent issue of the New England Journal of Medicine.
"These exciting data suggest that denosumab, when administered in twice-yearly injections, may show promise in the treatment of osteoporosis," said Michael McClung, MD, FACP, principal investigator of the denosumab study, Providence Portland Medical Center, and director of the Oregon Osteoporosis Center, Portland, Ore. "Continued research will further our understanding of the potential of denosumab in bone loss management."
Read more about Denosumab, the study design and osteoporosis from Amgen's press release.
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/16404
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for Amgen's Denosumab Increases Bone Mineral Density in Phase 2 Clinical Trials:
|
Rating: 8.00 out of 2 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
